Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 12/2016

12.09.2016 | Original Article

Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011

verfasst von: T. Qin, R. Bi, W. Fan, H. Kang, P. Ma, B. Gu

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the prevalence of fluoroquinolone resistance and mechanisms of selected fluoroquinolone resistance in Shigella flexneri isolates. A total of 624 S. flexneri strains isolated between 2001 and 2011 in Jiangsu Province of China were analysed for their fluoroquinolone susceptibility. The quinolone resistance-determining region of gyrA, gyrB, parC and parE were amplified and sequenced. In general, 90.5 % of S. flexneri exhibited resistance to nalidixic acid. The mean norfloxacin resistance rate was 22.4 % during the 11 years from 2001 to 2011 (6.4 % from 2001 to 2005 and 36.8 % from 2006 to 2011). Sequencing of gyrA, gyrB, parC and parE genes of all S. flexneri isolates showed that the mutation rate was as high as 93.9 %. In addition, 91.8 % and 92.3 % of S. flexneri harboured mutations in gyrA and parC, respectively. About 35.2 % of S. flexneri isolates susceptible to nalidixic acid contained mutations. Meanwhile, mutations were detected in 91.2 % of norfloxacin-susceptible strains, and almost all S. flexneri isolates resistant to fluoroquinolone contained mutations. To the best of our knowledge, this is the first study reporting the occurrence of point mutations Asn57Lys and His80Pro in gyrA and Ala85Thr, Asp111His and Ser129Pro in parC. Emerging fluoroquinolone resistance with a significantly high mutation rate of the gyrA and parC genes in S. flexneri in Jiangsu Province deserves attention, and monitoring antibiotic susceptibility is important for the effective management of S. flexneri infections.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE; Child Health Epidemiology Reference Group of the World Health Organization and UNICEF (2013) Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One 8, e72788CrossRefPubMedPubMedCentral Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE; Child Health Epidemiology Reference Group of the World Health Organization and UNICEF (2013) Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One 8, e72788CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S et al (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet 382:209–222CrossRefPubMed Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S et al (2013) Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet 382:209–222CrossRefPubMed
3.
Zurück zum Zitat Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ et al (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77:651–666PubMedPubMedCentral Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ et al (1999) Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 77:651–666PubMedPubMedCentral
5.
Zurück zum Zitat Shen Y, Qian H, Gong J, Deng F, Dong C, Zhou L et al (2013) High prevalence of antibiotic resistance and molecular characterization of integrons among Shigella isolates in Eastern China. Antimicrob Agents Chemother 57:1549–1551CrossRefPubMedPubMedCentral Shen Y, Qian H, Gong J, Deng F, Dong C, Zhou L et al (2013) High prevalence of antibiotic resistance and molecular characterization of integrons among Shigella isolates in Eastern China. Antimicrob Agents Chemother 57:1549–1551CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Klontz KC, Singh N (2015) Treatment of drug-resistant Shigella infections. Expert Rev Anti Infect Ther 13:69–80CrossRefPubMed Klontz KC, Singh N (2015) Treatment of drug-resistant Shigella infections. Expert Rev Anti Infect Ther 13:69–80CrossRefPubMed
7.
Zurück zum Zitat Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z et al (2012) Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009. Int J Antimicrob Agents 40:9–17CrossRefPubMed Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z et al (2012) Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009. Int J Antimicrob Agents 40:9–17CrossRefPubMed
8.
Zurück zum Zitat Pu XY, Pan JC, Zhang W, Zheng W, Wang HQ, Gu YM (2015) Quinolone resistance-determining region mutations and the plasmid-mediated quinolone resistance gene qnrS played important roles in decreased susceptibility to fluoroquinolones among Shigella isolates in southeast China between 1998 and 2013. Int J Antimicrob Agents 45:438–439CrossRefPubMed Pu XY, Pan JC, Zhang W, Zheng W, Wang HQ, Gu YM (2015) Quinolone resistance-determining region mutations and the plasmid-mediated quinolone resistance gene qnrS played important roles in decreased susceptibility to fluoroquinolones among Shigella isolates in southeast China between 1998 and 2013. Int J Antimicrob Agents 45:438–439CrossRefPubMed
9.
Zurück zum Zitat Yang H, Duan G, Zhu J, Zhang W, Xi Y, Fan Q (2013) Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008. Int J Antimicrob Agents 42:173–177CrossRefPubMed Yang H, Duan G, Zhu J, Zhang W, Xi Y, Fan Q (2013) Prevalence and characterisation of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes among Shigella isolates from Henan, China, between 2001 and 2008. Int J Antimicrob Agents 42:173–177CrossRefPubMed
10.
Zurück zum Zitat Fàbrega A, Madurga S, Giralt E, Vila J (2009) Mechanism of action of and resistance to quinolones. Microb Biotechnol 2:40–61CrossRefPubMed Fàbrega A, Madurga S, Giralt E, Vila J (2009) Mechanism of action of and resistance to quinolones. Microb Biotechnol 2:40–61CrossRefPubMed
11.
Zurück zum Zitat Qin TT, Kang HQ, Ma P, Li PP, Huang LY, Gu B (2015) SOS response and its regulation on the fluoroquinolone resistance. Ann Transl Med 3:358PubMedPubMedCentral Qin TT, Kang HQ, Ma P, Li PP, Huang LY, Gu B (2015) SOS response and its regulation on the fluoroquinolone resistance. Ann Transl Med 3:358PubMedPubMedCentral
12.
Zurück zum Zitat Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2):S120–S126CrossRefPubMed Jacoby GA (2005) Mechanisms of resistance to quinolones. Clin Infect Dis 41(Suppl 2):S120–S126CrossRefPubMed
13.
14.
Zurück zum Zitat Li XZ (2005) Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 25:453–463CrossRefPubMed Li XZ (2005) Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 25:453–463CrossRefPubMed
15.
Zurück zum Zitat Cui X, Wang J, Yang C, Liang B, Ma Q, Yi S et al (2015) Prevalence and antimicrobial resistance of Shigella flexneri serotype 2 variant in China. Front Microbiol 6:435CrossRefPubMedPubMedCentral Cui X, Wang J, Yang C, Liang B, Ma Q, Yi S et al (2015) Prevalence and antimicrobial resistance of Shigella flexneri serotype 2 variant in China. Front Microbiol 6:435CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C et al (2011) Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother 66:2527–2535CrossRefPubMed Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C et al (2011) Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother 66:2527–2535CrossRefPubMed
17.
Zurück zum Zitat Pu XY, Pan JC, Wang HQ, Zhang W, Huang ZC, Gu YM (2009) Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China. J Antimicrob Chemother 63:917–920CrossRefPubMed Pu XY, Pan JC, Wang HQ, Zhang W, Huang ZC, Gu YM (2009) Characterization of fluoroquinolone-resistant Shigella flexneri in Hangzhou area of China. J Antimicrob Chemother 63:917–920CrossRefPubMed
18.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—Ninth edition. CLSI document M07-A9. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard—Ninth edition. CLSI document M07-A9. CLSI, Wayne, PA
19.
Zurück zum Zitat Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT et al (2007) Antimicrobial drug resistance of Salmonella enterica serovar typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 51:4315–4323CrossRefPubMedPubMedCentral Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT et al (2007) Antimicrobial drug resistance of Salmonella enterica serovar typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 51:4315–4323CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Dutta S, Kawamura Y, Ezaki T, Nair GB, Iida K, Yoshida S (2005) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India. Antimicrob Agents Chemother 49:1660–1661CrossRefPubMedPubMedCentral Dutta S, Kawamura Y, Ezaki T, Nair GB, Iida K, Yoshida S (2005) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India. Antimicrob Agents Chemother 49:1660–1661CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rahman M, Mauff G, Levy J, Couturier M, Pulverer G, Glasdorff N et al (1994) Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob Agents Chemother 38:2488–2491CrossRefPubMedPubMedCentral Rahman M, Mauff G, Levy J, Couturier M, Pulverer G, Glasdorff N et al (1994) Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob Agents Chemother 38:2488–2491CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Christopher PR, David KV, John SM, Sankarapandian V (2010) Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev (8):CD006784 Christopher PR, David KV, John SM, Sankarapandian V (2010) Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev (8):CD006784
23.
Zurück zum Zitat Özmert EN, İnce OT, Örün E, Yalçın S, Yurdakök K, Gür D (2011) Clinical characteristics and antibiotic resistance of Shigella gastroenteritis in Ankara, Turkey between 2003 and 2009, and comparison with previous reports. Int J Infect Dis 15:e849–853CrossRefPubMed Özmert EN, İnce OT, Örün E, Yalçın S, Yurdakök K, Gür D (2011) Clinical characteristics and antibiotic resistance of Shigella gastroenteritis in Ankara, Turkey between 2003 and 2009, and comparison with previous reports. Int J Infect Dis 15:e849–853CrossRefPubMed
24.
Zurück zum Zitat Qu M, Zhang X, Liu G, Huang Y, Jia L, Liang W et al (2014) An eight-year study of Shigella species in Beijing, China: serodiversity, virulence genes, and antimicrobial resistance. J Infect Dev Ctries 8:904–908CrossRefPubMed Qu M, Zhang X, Liu G, Huang Y, Jia L, Liang W et al (2014) An eight-year study of Shigella species in Beijing, China: serodiversity, virulence genes, and antimicrobial resistance. J Infect Dev Ctries 8:904–908CrossRefPubMed
25.
Zurück zum Zitat Zhang CL, Liu QZ, Wang J, Chu X, Shen LM, Guo YY (2014) Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China. BMC Infect Dis 14:260CrossRefPubMedPubMedCentral Zhang CL, Liu QZ, Wang J, Chu X, Shen LM, Guo YY (2014) Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China. BMC Infect Dis 14:260CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Qiu S, Xu X, Yang C, Wang J, Liang B, Li P et al (2015) Shift in serotype distribution of Shigella species in China, 2003–2013. Clin Microbiol Infect 21:252.e5–252.e8CrossRef Qiu S, Xu X, Yang C, Wang J, Liang B, Li P et al (2015) Shift in serotype distribution of Shigella species in China, 2003–2013. Clin Microbiol Infect 21:252.e5–252.e8CrossRef
27.
Zurück zum Zitat Zhang J, Jin H, Hu J, Yuan Z, Shi W, Yang X et al (2014) Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004–2011. Diagn Microbiol Infect Dis 78:282–286CrossRefPubMed Zhang J, Jin H, Hu J, Yuan Z, Shi W, Yang X et al (2014) Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004–2011. Diagn Microbiol Infect Dis 78:282–286CrossRefPubMed
28.
Zurück zum Zitat Abd-Elmeged GM, Khairy RM, Abo-Eloyoon SM, Abdelwahab SF (2015) Changing patterns of drug-resistant Shigella isolates in Egypt. Microb Drug Resist 21:286–291CrossRefPubMed Abd-Elmeged GM, Khairy RM, Abo-Eloyoon SM, Abdelwahab SF (2015) Changing patterns of drug-resistant Shigella isolates in Egypt. Microb Drug Resist 21:286–291CrossRefPubMed
29.
Zurück zum Zitat Hu LF, Li JB, Ye Y, Li X (2007) Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China. J Microbiol 45:168–170PubMed Hu LF, Li JB, Ye Y, Li X (2007) Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China. J Microbiol 45:168–170PubMed
30.
Zurück zum Zitat Tariq A, Haque A, Ali A, Bashir S, Habeeb MA, Salman M et al (2012) Molecular profiling of antimicrobial resistance and integron association of multidrug-resistant clinical isolates of Shigella species from Faisalabad, Pakistan. Can J Microbiol 58:1047–1054CrossRefPubMed Tariq A, Haque A, Ali A, Bashir S, Habeeb MA, Salman M et al (2012) Molecular profiling of antimicrobial resistance and integron association of multidrug-resistant clinical isolates of Shigella species from Faisalabad, Pakistan. Can J Microbiol 58:1047–1054CrossRefPubMed
31.
Zurück zum Zitat Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay EJ, Krueger A et al (2012) Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000–2010. Clin Infect Dis 54(Suppl 5):S458–S463CrossRefPubMed Shiferaw B, Solghan S, Palmer A, Joyce K, Barzilay EJ, Krueger A et al (2012) Antimicrobial susceptibility patterns of Shigella isolates in Foodborne Diseases Active Surveillance Network (FoodNet) sites, 2000–2010. Clin Infect Dis 54(Suppl 5):S458–S463CrossRefPubMed
32.
Zurück zum Zitat Cui X, Yang C, Wang J, Liang B, Yi S, Li H et al (2015) Antimicrobial resistance of Shigella flexneri serotype 1b isolates in China. PLoS One 10, e0129009CrossRefPubMedPubMedCentral Cui X, Yang C, Wang J, Liang B, Yi S, Li H et al (2015) Antimicrobial resistance of Shigella flexneri serotype 1b isolates in China. PLoS One 10, e0129009CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Mao Y, Cui E, Bao C, Liu Z, Chen S, Zhang J et al (2013) Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010. Gut Pathog 5:21CrossRefPubMedPubMedCentral Mao Y, Cui E, Bao C, Liu Z, Chen S, Zhang J et al (2013) Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010. Gut Pathog 5:21CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Xia S, Xu B, Huang L, Zhao JY, Ran L, Zhang J et al (2011) Prevalence and characterization of human Shigella infections in Henan Province, China, in 2006. J Clin Microbiol 49:232–242CrossRefPubMed Xia S, Xu B, Huang L, Zhao JY, Ran L, Zhang J et al (2011) Prevalence and characterization of human Shigella infections in Henan Province, China, in 2006. J Clin Microbiol 49:232–242CrossRefPubMed
35.
Zurück zum Zitat Thompson CN, Thieu NT, Vinh PV, Duc AN, Wolbers M, Vinh H et al (2016) Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections. J Antimicrob Chemother 71:807–815CrossRefPubMed Thompson CN, Thieu NT, Vinh PV, Duc AN, Wolbers M, Vinh H et al (2016) Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections. J Antimicrob Chemother 71:807–815CrossRefPubMed
36.
Zurück zum Zitat Ruiz J (2003) Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109–1117CrossRefPubMed Ruiz J (2003) Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 51:1109–1117CrossRefPubMed
37.
38.
Zurück zum Zitat Azmi IJ, Khajanchi BK, Akter F, Hasan TN, Shahnaij M, Akter M et al (2014) Fluoroquinolone resistance mechanisms of Shigella flexneri isolated in Bangladesh. PLoS One 9, e102533CrossRefPubMedPubMedCentral Azmi IJ, Khajanchi BK, Akter F, Hasan TN, Shahnaij M, Akter M et al (2014) Fluoroquinolone resistance mechanisms of Shigella flexneri isolated in Bangladesh. PLoS One 9, e102533CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Taneja N, Mishra A, Kumar A, Verma G, Sharma M (2015) Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region. Indian J Med Res 141:81–89CrossRefPubMedPubMedCentral Taneja N, Mishra A, Kumar A, Verma G, Sharma M (2015) Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region. Indian J Med Res 141:81–89CrossRefPubMedPubMedCentral
Metadaten
Titel
Novel mutations in quinolone resistance-determining regions of gyrA, gyrB, parC and parE in Shigella flexneri clinical isolates from eastern Chinese populations between 2001 and 2011
verfasst von
T. Qin
R. Bi
W. Fan
H. Kang
P. Ma
B. Gu
Publikationsdatum
12.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 12/2016
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2761-2

Weitere Artikel der Ausgabe 12/2016

European Journal of Clinical Microbiology & Infectious Diseases 12/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.